WARREN, N.J., July 31, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced that Keith Kendall, Chief Executive Officer, and John Maxwell, Chief Financial Officer, will present at the 2018 Wedbush Healthcare Conference to be held in New York, NY on August 14-15.
Aquestive will present on Tuesday, August 14 at 12:45 p.m. Eastern Daylight Time (EDT). A webcast of the presentation will be available on the "Investors" section of the IR website. For more information, please visit investors.aquestive.com.
About Aquestive TherapeuticsAquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.
Media inquiries:Christopher Hippolyte[email protected]212-364-0458
Investor inquiries:Stephanie Carrington[email protected]646-277-1282
Advertisement
Aquestive will present on Tuesday, August 14 at 12:45 p.m. Eastern Daylight Time (EDT). A webcast of the presentation will be available on the "Investors" section of the IR website. For more information, please visit investors.aquestive.com.
Advertisement
About Aquestive TherapeuticsAquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.
Media inquiries:Christopher Hippolyte[email protected]212-364-0458
Investor inquiries:Stephanie Carrington[email protected]646-277-1282
View original content:http://www.prnewswire.com/news-releases/aquestive-therapeutics-to-present-at-the-2018-wedbush-healthcare-conference-300688864.html
SOURCE Aquestive Therapeutics
